Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality

Neurology

Volumn 47, Issue 1, 1996, Pages 166-177

  Knopman, D ^a,d   Schneider, L ^b,d   Davis, K ^c,d   Talwalker, S ^d   Smith, F ^d   Hoover, T ^d   Gracon, S ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACRINE;

ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; NURSING HOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0030035653     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.1.166     Document Type: Article

References (35)

1. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529.
2. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
3. Lieberman MA, Kramer JH. Factors affecting decisions to institutionalize demented elderly. Gerontologist 1991;31:371-374.
4. Colerick EJ, George LK. Predictors of institutionalization among caregivers of patients with Alzheimer's disease. J Am Geriatr Soc 1986;34:493-498.
5. Brodaty H, McGilchrist C, Harris L, Peters KE. Time until institutionalization and death in patients with dementia. Role of caregiver training and risk factors. Arch Neurol 1993;50: 643-650.
6. O'Donnell BF, Drachman DA, Barnes HJ, Peterson KE, Swearer JM, Lew RA. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992;5:45-52.
7. Cohen CA, Gold DP, Shulman KI, Wortley JT, McDonald G, Wargon M. Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist 1993;33:714-720.
8. Severson MA, Smith GE, Tangalos EG, et al. Patterns and predictors of institutionalization in community-based dementia patients. J Am Geriatr Soc 1994;42:181-185.
9. Rice DP, Fox PJ, Hauch WW, et al. The burden of caring for Alzheimer's disease patients. Proceedings of the 1991 Public Health Conference on Records and Statistics, 1991:119-124.
10. Knopman DS, Kitto J, Deinard S, Heiring J. Longitudinal study of death and institutionalization in patients with primary degenerative dementia. J Am Geriatr Soc 1988;36:108-112.
11. Welch HG, Walsh JS, Larson EB. The cost of institutional care in Alzheimer's disease: nursing home and hospital use in a prospective cohort. J Am Geriatr Soc 1992;40:221-224.
12. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994;331:394-398.
13. Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med 1993;329:2029-2032.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-944.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
16. Reisberg B, Ferris SH, de Leon MJ, et al. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
17. Lawton MP, Brodie EM. Assessment of older people: self-maintenance and instrumental activities of daily living. Gerontologist 1969;9:176-186.
18. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
19. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 1994;51:676-681.
20. SAS Institute, Inc. SAS/STAT user's guide, version 6. 4th ed., Vol. 2. Cary, NC: SAS Institute, Inc., 1990.
21. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research. Belmont, CA: Lifetime Learning Publications, 1982.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
23. Horwitz RI, Viscoli CM, Clemens JD, Sadock RT. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med 1990;89:630-638.
24. Goldman L, Hiatt H. Randomized trials [letter]. Nature 1995; 373:378.
25. Smith GD, Phillips AN, Neaton JD. Smoking as "independent" risk factor for suicide: illustration of an artifact from observational epidemiology. Lancet 1992;340:709-712.
26. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzhelmer's disease. N Engl J Med 1992;327:1253-1259.
27. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991;337:989-992.
28. Eagger SA, Richards M, Levy R. Long-term effects of tacrine in Alzheimer's disease: an open study. Int J Geriatr Psychiatry 1994;9:643-647.
29. Wilcock GK, Scott M, Pearsall T. Long-term use of tacrine [letter]. Lancet 1994;343:294.
30. Nordberg A. Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET. Acta Neurol Scand 1993;(suppl 149):62-65.
31. Amberla K, Nordberg A, Viitanen M, Winblad B. Long-term treatment with tacrine (THA) in Alzheimer's disease-evaluation of neuropsychological data. Acta Neurol Scand 1993; (suppl 149):55-57.
32. Maltby N, Broe GA, Creasey H, Jorm AF, Christensen H, Brooks WS. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial. BMJ 1994;308: 879-883.
33. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of beta-amyloid precursor protein in cell lines. J Neurosci Res 1994;37:777-787.
34. Kaufer DI, Cummings JL, Christine D. Effects of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
35. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empiric evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412.